Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBT Margin (2019 - 2025)

Avidity Biosciences (RNA) has disclosed EBT Margin for 7 consecutive years, with 7095.17% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 364889.0% year-over-year to 7095.17%, compared with a TTM value of 3215.68% through Dec 2025, down 26023.0%, and an annual FY2025 reading of 3640.03%, down 68459.0% over the prior year.
  • EBT Margin was 7095.17% for Q4 2025 at Avidity Biosciences, down from 1395.29% in the prior quarter.
  • Across five years, EBT Margin topped out at 881.69% in Q1 2021 and bottomed at 7332.36% in Q1 2025.
  • Average EBT Margin over 5 years is 2702.0%, with a median of 2050.92% recorded in 2021.
  • Peak annual rise in EBT Margin hit 203648bps in 2025, while the deepest fall reached -539180bps in 2025.
  • Year by year, EBT Margin stood at 2078.4% in 2021, then grew by 12bps to 1822.07% in 2022, then plummeted by -51bps to 2751.39% in 2023, then fell by -25bps to 3446.28% in 2024, then tumbled by -106bps to 7095.17% in 2025.
  • Business Quant data shows EBT Margin for RNA at 7095.17% in Q4 2025, 1395.29% in Q3 2025, and 4072.37% in Q2 2025.